Compare HERE & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HERE | CRBU |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | China | United States |
| Employees | 714 | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.1M | 158.2M |
| IPO Year | N/A | 2021 |
| Metric | HERE | CRBU |
|---|---|---|
| Price | $2.25 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 164.2K | ★ 1.8M |
| Earning Date | 06-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | $79.29 | $10.93 |
| P/E Ratio | $2.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $1.12 |
| 52 Week High | $5.80 | $3.53 |
| Indicator | HERE | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 32.89 |
| Support Level | $2.03 | $1.39 |
| Resistance Level | $2.50 | $1.73 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 74.50 | 4.44 |
Here Group Ltd is dedicated to creating collectible pop toys that evoke joy and emotional resonance. The group design and compelling storytelling, which provide users with a collecting experience that blends artistic value with emotional warmth, continuously convey a joyful and immersive brand culture. Adhering to the brand philosophy of joy, integrity, wonder, and co-creation, the company is building a vibrant ecosystem connecting creativity and emotion, working hand-in-hand with overall toy enthusiasts to create, share, and transmit dreams.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.